News

Propensity Matching Matters in Comparing Radiation Therapy and Radical Cystectomy

Update on Use of Perioperative Chemotherapy for High-Grade Upper Tract Urothelial Cancer

Targeting CDCP1 Cell-Surface Protein Via Radiotherapy in Metastatic Bladder Cancer

Phase II Trial Update on Potential Bladder-Sparing Treatment

ASCO GU 2023: Extended Follow-up From CheckMate 274 With Nivolumab for High-Risk Urothelial Carcinoma

Novel Targeted Aptamer-Drug Conjugate Under Study in Bladder Cancer

ASCO GU 2023: Update From KEYNOTE-057 on Pembrolizumab Monotherapy for Aggressive Bladder Cancer

ASCO GU 2023: Overall Survival Update From IMvigor130 on Atezolizumab Versus Chemotherapy for Advanced Urothelial Carcinoma

ASCO GU 2023: Predicting Outcomes With Enfortumab Vedotin in Advanced Urothelial Carcinoma

ASCO GU 2023: TROPHY-U-01 Update Supports Further Evaluation of Sacituzumab Govitecan in Urothelial Cancer

Prognostic Factors of Secondary Bladder Cancer After Radical Surgery for Urothelial Carcinoma

Study Finds Room for Improvement in Assessing Quality of Life in Patients With Bladder Cancer

Study Centers on Key Role of the E3 Ligase RFWD3 in Bladder Cancer

Can Decreased Nectin-4 Expression Predict Resistance to Enfortumab Vedotin in Urothelial Carcinoma?

Can a Genetic Signature Be Used to Predict Clinical Outcomes in Bladder Cancer?

A Novel Tool for Risk Assessment and Personalized Care for Patients With Bladder Cancer

Phase II TALASUR Trial to Study Maintenance Talazoparib Plus Avelumab in Urothelial Carcinoma

Methylation of PENK: Potential Biomarker for Early Detection of Bladder Cancer?

Rogaratinib Versus Chemotherapy for Advanced Urothelial Carcinoma: Phase II Trial Results

First Gene Therapy for High-Risk, Non–Muscle-Invasive Bladder Cancer Approved by the FDA

Shedding Research Light on the OAS Gene Family in Bladder Cancer

Can Single-Port Robotic Surgery Improve Cosmesis After Bladder Procedures?

Is Infection With Human Polyomavirus a Causative Factor in Bladder Cancer in Southern Iran?

Is Progression of Bladder Cancer Influenced by the KDELR2-KIF20A Axis? Researchers in China Say Yes

SITC 2022: Avelumab-Based Combination Therapy for Advanced Urothelial Carcinoma

Risk-Aligned Bladder Cancer Surveillance: Data-Driven Approach to Implementation Mapping

SITC 2022: Phase II Trial Update on Vaccine Plus Pembrolizumab in Resistant Bladder Cancer

ASTRO 2022: Comparison of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer

ASTRO 2022: Can Genetic Mutations Determine Response to Trimodality Therapy in Bladder Cancer?

ASTRO 2022: Adding Pelvic Lymph Node Treatment to Bladder-Sparing Chemoradiotherapy for Bladder Cancer

ASTRO 2022: Radiotherapy Versus Surgery for Node-Positive, Nonmetastatic Bladder Cancer

The Role of Memory Immune and Effector Cells in Early Progression of Bladder Cancer

YAP1 Activation: A Potential Prognostic and Therapeutic Factor in Bladder Cancer

A Novel Gene Signature May Help Predict the Prognosis of Bladder Urothelial Carcinoma

Can Photodynamic-Guided Surgery in Non–Muscle-Invasive Bladder Cancer Reduce Recurrences?

Tislelizumab Plus Chemotherapy as First-Line Adjuvant Treatment of Advanced Bladder Cancer

Can Alternative Splicing Help to Reveal a Prognostic Biomarker in Muscle-Invasive Bladder Cancer?

Advanced Urothelial Carcinoma: Combination of Soluble EphB4-Human Serum Albumin Plus Pembrolizumab